Tag
This meta-analysis consolidates data from six RCTs comparing left atrial appendage closure (LAAC) to oral anticoagulation for stroke prevention in atrial fibrillation, highlighting reduced bleeding with LAAC but increased ischemic stroke ri
The AZALEA-TIMI 71 study demonstrates that factor XI inhibition with abelacimab reduces bleeding risk in atrial fibrillation patients regardless of prior oral anticoagulation experience, with a potentially greater absolute benefit in antico
Shorter pre-treatment fibrin clot lysis time independently predicts higher bleeding risk in AF patients on oral anticoagulation, as evidenced by the ARISTOTLE trial.
A large target‑trial emulation of US claims data found continued oral anticoagulation after ≥90 days for unprovoked VTE markedly reduced recurrent VTE and mortality, increased major bleeding, but produced an overall net clinical benefit tha
In the ADAPT AF‑DES randomized trial, NOAC monotherapy in AF patients with drug‑eluting stents implanted ≥1 year earlier reduced bleeding and was noninferior—and numerically superior—for a composite of ischemic and bleeding outcomes versus
A randomized trial revealed that adding aspirin to oral anticoagulation in chronic coronary syndrome patients increases adverse cardiovascular events, mortality, and major bleeding, challenging conventional dual therapy approaches.
